therascreen® BRAF V600E RGQ PCR Kit by QIAGEN

Manufacturer QIAGEN
3.7
/
5.0
  |  1 reviews

For qualitative detection of V600E mutations in the BRAF gene using real-time PCR


therascreen® BRAF V600E RGQ PCR Kit by QIAGEN product image
therascreen® BRAF V600E RGQ PCR Kit



Average Rating: 3.7
1 Scientist has reviewed this product

3 out of 5
Ease of use
4 out of 5
After sales service
4 out of 5
Value for money


  • Status:

    Reviewer
  • Member since: 2020

  • Organization: Narayana Hrudayalaya Institute Of Cardiac Sciences



  • Ease of use
    3 out of 5
    After sales service
    4 out of 5
    Value for money
    4 out of 5
Share this Review on LinkedinShare this Review on TwitterShare this Review on Facebook
Great.
Rating: 3.7

  • Application Area: Personalized treatments that target genetic changes

"The product is very useful especially in CRC patients and we are able to define personalized care in this subgroup. Only a small amount of the tissue is required and hence without hampering other test we can get it done."

Review date: 16 Jun 2021 | therascreen® BRAF V600E RGQ PCR Kit

The therascreen BRAF V600E RGQ PCR Kit is a qualitative in vitro diagnostic test for the detection of V600E mutations in the BRAF gene. The test analyzes DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue, taken from a patient with colorectal cancer (CRC). It is intended to aid clinicians in identifying metastatic colorectal cancer (mCRC) patients eligible for treatment with BRAFTOVI (encorafenib) in combination with cetuximab.

Features

  • FDA-approved BRAF mutation companion diagnostic test
  • Reliable detection of V600E mutations in the BRAF gene
  • High sensitivity and specificity
  • Simple workflow from sample to insight
  • Automated data analysis using Rotor-Gene AssayManager for fast, easy result determination

Product Overview

therascreen® BRAF V600E RGQ PCR Kit by QIAGEN product image

therascreen® BRAF V600E RGQ PCR Kit

Manufacturer QIAGEN

3.7 / 5.0 | 1 reviews